AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10364948 — intervention group
Group type: EXPERIMENTAL
Intervention: PIN stripping of the long saphenous vein (LSV)
Number of subjects: 80
Study 10364948 — intervention group
Group type: COMPARATOR
Intervention: Conventional stripping
Number of subjects: 80
Study 8727845 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal education and maternal responsiveness
Number of subjects: 182
Study 8727845 — intervention group
Group type: COMPARATOR
Intervention: Maternal education alone
Number of subjects: 182
Study 1984898 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 623
Study 1984898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 623
Study 6851273 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol, 200 mg daily
Number of subjects: 6
Study 6851273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 27561310 — intervention group
Group type: EXPERIMENTAL
Intervention: PROMIS static short-form instruments
Number of subjects: 0
Study 27013068 — intervention group
Group type: EXPERIMENTAL
Intervention: Fellow eye trabeculectomy
Number of subjects: 159
Study 27013068 — intervention group
Group type: COMPARATOR
Intervention: Fellow eye surgery refusal
Number of subjects: 159
Study 27013068 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased fellow eye preoperative intraocular pressure (IOP)
Number of subjects: 159
Study 27013068 — intervention group
Group type: EXPERIMENTAL
Intervention: Study eye hypotony at 3 months postoperatively
Number of subjects: 159
Study 27013068 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon suture lysis procedure
Number of subjects: 159
Study 24508634 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 200 U
Number of subjects: 315
Study 24508634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315
Study 22608478 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Number of subjects: 42
Study 22608478 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cataract surgery)
Number of subjects: 42
Study 21128060 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 monotherapy (40 mg/m², orally twice daily, days 1-28, every 6 weeks)
Number of subjects: 153
Study 17951625 — intervention group
Group type: EXPERIMENTAL
Intervention: SFC (salmeterol 50 microg/fluticasone 500 microg, twice daily)
Number of subjects: 445
Study 17951625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 445
Study 15871736 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacto-vegetarian, vegan or Mediterranean diets
Number of subjects: 95
Study 15871736 — intervention group
Group type: COMPARATOR
Intervention: Ordinary diet
Number of subjects: 95
Study 12503832 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 9
Study 12503832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 10941382 — intervention group
Group type: EXPERIMENTAL
Intervention: Kapandji's intrafocal pinning (Group I)
Number of subjects: 88
Study 10941382 — intervention group
Group type: COMPARATOR
Intervention: Py's isoelastic pinning (Group II)
Number of subjects: 88
Study 8599586 — intervention group
Group type: EXPERIMENTAL
Intervention: Zenith Premium alloy
Number of subjects: 2
Study 8599586 — intervention group
Group type: COMPARATOR
Intervention: Valiant PhD alloy
Number of subjects: 2
Study 2801590 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid cow-milk-based formula containing 1.3 mumol Cu/L (n = 16)
Number of subjects: 200
Study 2801590 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid cow-milk-based formula supplemented with 7.8 mumol Cu/L as Cu sulfate (n = 16)
Number of subjects: 200
Study 2801590 — intervention group
Group type: COMPARATOR
Intervention: Exclusively breast-fed infants
Number of subjects: 200
Study 30125376 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg/kg acetylcysteine over 12 hours
Number of subjects: 100
Study 30125376 — intervention group
Group type: COMPARATOR
Intervention: 300 mg/kg acetylcysteine over 20 hours
Number of subjects: 100
Study 28845931 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant antioxidant therapy with SpermActin-forte (SA)
Number of subjects: 114
Study 28845931 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant antioxidant therapy with SpermActin-forte (SA) and vitamin complex (VC)
Number of subjects: 114
Study 28845931 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant therapy (Control)
Number of subjects: 114
Study 25727806 — intervention group
Group type: EXPERIMENTAL
Intervention: Active support
Number of subjects: 80
Study 25727806 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive support
Number of subjects: 80
Study 25727806 — intervention group
Group type: COMPARATOR
Intervention: Control (intimacy effect)
Number of subjects: 80
Study 25117173 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir 60 mg once daily and asunaprevir 200 mg twice daily (combination dosing for 14 days)
Number of subjects: 0
Study 25117173 — intervention group
Group type: COMPARATOR
Intervention: Daclatasvir and asunaprevir administered together or alone in HCV patients
Number of subjects: 0
Study 22159659 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 894
Study 21949794 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-down bed rest (BR)
Number of subjects: 20
Study 21949794 — intervention group
Group type: COMPARATOR
Intervention: Sitting control condition
Number of subjects: 20
Study 18041485 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg zolpidem
Number of subjects: 12
Study 18041485 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg zaleplon
Number of subjects: 12
Study 18041485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 16119487 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ketamine (1 mg/kg) with priming (0.04 mg/kg of rocuronium)
Number of subjects: 60
Study 16119487 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ketamine (1 mg/kg) without priming
Number of subjects: 60
Study 16119487 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone (4 mg/kg) with priming (0.04 mg/kg of rocuronium)
Number of subjects: 60
Study 16119487 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone (4 mg/kg) without priming
Number of subjects: 60
Study 16119487 — intervention group
Group type: COMPARATOR
Intervention: Control group (sham priming with saline) with S-ketamine (1 mg/kg)
Number of subjects: 60
Study 16119487 — intervention group
Group type: COMPARATOR
Intervention: Control group (sham priming with saline) with thiopentone (4 mg/kg)
Number of subjects: 60
Study 12296586 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily treatment (full-mouth daily scaling and root planing for 4 consecutive days)
Number of subjects: 100
Study 12296586 — intervention group
Group type: COMPARATOR
Intervention: Weekly treatment (once a week for 4 weeks)
Number of subjects: 100
Study 10073377 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0
Study 10073377 — intervention group
Group type: COMPARATOR
Intervention: Conventional antipsychotic drugs
Number of subjects: 0
Study 8629068 — intervention group
Group type: EXPERIMENTAL
Intervention: mebendazole plus pyrantel oxantel pamoate every three months
Number of subjects: 353
Study 8629068 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 353
Study 2202705 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate 1 g four times daily
Number of subjects: 0
Study 2202705 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 0
Study 2202705 — intervention group
Group type: COMPARATOR
Intervention: Sucralfate
Number of subjects: 0
Study 2202705 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 0
Study 6110957 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinic acid (25 mg)
Number of subjects: 0
Study 6110957 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 0
Study 6110957 — intervention group
Group type: EXPERIMENTAL
Intervention: Benorylate
Number of subjects: 0
Study 6110957 — intervention group
Group type: COMPARATOR
Intervention: Naloxone
Number of subjects: 0
Study 30912713 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Group (EG): autonomy supportive teaching enriched with high levels of competence support and relatedness support
Number of subjects: 160
Study 30912713 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG): autonomy supportive teaching enriched with basic levels of competence support and relatedness support
Number of subjects: 160
Study 30912713 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups assessed at three time points (T1, T2, T3) for perceived moderation competence and emotions, with grades from a practical moderation exam at T3.
Number of subjects: 160
Study 28220040 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to vigorous physical activity (MVPA)
Number of subjects: 236
Study 28220040 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 236
Study 25290685 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine advice on wound management
Number of subjects: 90
Study 25290685 — intervention group
Group type: COMPARATOR
Intervention: Conventional practice
Number of subjects: 90
Study 24074879 — intervention group
Group type: EXPERIMENTAL
Intervention: NPLD (60 mg/mq iv) plus cyclophosphamide (600 mg/mq iv) every 3 weeks for 4 cycles followed by docetaxel (35 mg/mq iv) plus trastuzumab (4 mg/mq loading dose iv, then 2 mg/mq iv) weekly for 16 weeks
Number of subjects: 43
Study 24074879 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-PET
Number of subjects: 43
Study 21356075 — intervention group
Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 156
Study 21356075 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 156
Study 19648746 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete removal of carious dentin using a caries detector dye
Number of subjects: 32
Study 19648746 — intervention group
Group type: COMPARATOR
Intervention: Partial removal of carious dentin (only superficial removal of necrotic carious dentin from the cavity floor)
Number of subjects: 32
Study 19648746 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups after sealing
Number of subjects: 32
Study 17465348 — intervention group
Group type: EXPERIMENTAL
Intervention: Grafted group (autogenous bone harvested from the mandibular symphysis)
Number of subjects: 15
Study 17465348 — intervention group
Group type: COMPARATOR
Intervention: Nongrafted group (no grafting)
Number of subjects: 15
Study 17465348 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 15
Study 15452611 — intervention group
Group type: EXPERIMENTAL
Intervention: Epithalamin (peptide preparation from the pineal gland)
Number of subjects: 0
Study 11552904 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg b.d.
Number of subjects: 82
Study 11552904 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg o.m.
Number of subjects: 82
Study 11552904 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg o.m.
Number of subjects: 82
Study 11552904 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 9041069 — intervention group
Group type: EXPERIMENTAL
Intervention: Balke treadmill protocol
Number of subjects: 38
Study 9041069 — intervention group
Group type: COMPARATOR
Intervention: Bruce treadmill protocol
Number of subjects: 38
Study 9041069 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender comparison
Number of subjects: 38
Study 7932809 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 62
Study 7932809 — intervention group
Group type: COMPARATOR
Intervention: No-tamoxifen
Number of subjects: 62
Study 3177073 — intervention group
Group type: EXPERIMENTAL
Intervention: Free smoking in a structured context
Number of subjects: 0
Study 30449654 — intervention group
Group type: EXPERIMENTAL
Intervention: High goal impact condition
Number of subjects: 68
Study 30449654 — intervention group
Group type: COMPARATOR
Intervention: Low goal impact condition
Number of subjects: 68
Study 27063478 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambrisentan (10 mg per day)
Number of subjects: 28
Study 27063478 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 24943851 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated treatment Simultaneously Targeting Obesity and Pain (STOP)
Number of subjects: 0
Study 24943851 — intervention group
Group type: COMPARATOR
Intervention: Standard care behavioral weight loss
Number of subjects: 0
Study 24943851 — intervention group
Group type: COMPARATOR
Intervention: Standard care behavioral pain management
Number of subjects: 0
Study 22627057 — intervention group
Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate suspension 0.2% administered QID
Number of subjects: 300
Study 22627057 — intervention group
Group type: COMPARATOR
Intervention: Olopatadine solution 0.1% administered BID
Number of subjects: 300
Study 20689824 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide for 28 days
Number of subjects: 0
Study 20689824 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study 19137888 — intervention group
Group type: EXPERIMENTAL
Intervention: Open reduction and pulling out wire (Group A)
Number of subjects: 72
Study 19137888 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous pinning with plaster splint (Group B)
Number of subjects: 72
Study 15869587 — intervention group
Group type: EXPERIMENTAL
Intervention: Second generation oral contraceptives
Number of subjects: 7
Study 15869587 — intervention group
Group type: EXPERIMENTAL
Intervention: Third generation oral contraceptives
Number of subjects: 7
Study 12534456 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg day-1 for 3 weeks
Number of subjects: 59
Study 12534456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 9588621 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat Meal (FM)
Number of subjects: 9
Study 8570773 — intervention group
Group type: EXPERIMENTAL
Intervention: Biperiden (Akineton) 12 mg/day for 4 weeks
Number of subjects: 0
Study 8570773 — intervention group
Group type: COMPARATOR
Intervention: Glycopyrrolate (Robinul) 1 mg/day for 4 weeks
Number of subjects: 0
Study 8570773 — intervention group
Group type: EXPERIMENTAL
Intervention: Biperiden (Akineton) 12 mg/day for 1 week
Number of subjects: 0
Study 8570773 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 1 week
Number of subjects: 0
Study 8570773 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 1 week (week 6)
Number of subjects: 0
Study 1700927 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined modality therapy (chemotherapy followed by radiation therapy)
Number of subjects: 46
Study 1700927 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 46
Study 535132 — intervention group
Group type: EXPERIMENTAL
Intervention: Divided dose regimen of 25 mg methotrexate taken at 2-hour intervals (total 100 mg)
Number of subjects: 0
Study 535132 — intervention group
Group type: COMPARATOR
Intervention: Single 100 mg oral dose of methotrexate
Number of subjects: 0
Study 31586602 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive radical hysterectomy (n=279)
Number of subjects: 631
Study 31586602 — intervention group
Group type: COMPARATOR
Intervention: Open radical hysterectomy (n=257)
Number of subjects: 631
Study 31789301 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive-visual feedback during walking for 30 minutes, 3 times/week for 8 weeks
Number of subjects: 30
Study 31789301 — intervention group
Group type: COMPARATOR
Intervention: Regular therapeutic exercise program for 1 hour, walking for 30 minutes without feedback
Number of subjects: 30
Study 27439114 — intervention group
Group type: EXPERIMENTAL
Intervention: Lauromacrogol-cyanoacrylate-lauromacrogol
Number of subjects: 96
Study 27439114 — intervention group
Group type: COMPARATOR
Intervention: Lipiodol-cyanoacrylate-lipiodol
Number of subjects: 96
Study 27439114 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 96
Study 25867230 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional training (FT) program consisting of two sessions a week of in-water exercise and one of on-land exercise for 18 weeks
Number of subjects: 36
Study 25867230 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional training (FT) program
Number of subjects: 36
Study 23593417 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH 3 mg daily
Number of subjects: 77
Study 23593417 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone 4 mg twice daily
Number of subjects: 77
Study 23593417 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination rhGH + rosiglitazone
Number of subjects: 77
Study 23593417 — intervention group
Group type: COMPARATOR
Intervention: Double placebo (control)
Number of subjects: 77
Study 23593417 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH/rosiglitazone
Number of subjects: 77
Study 23593417 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH
Number of subjects: 77
Study 23593417 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone alone
Number of subjects: 77
Study 23593417 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 77
Study 23593417 — intervention group
Group type: EXPERIMENTAL
Intervention: All arms
Number of subjects: 77
Study 21831993 — intervention group
Group type: COMPARATOR
Intervention: SFA-rich drinks
Number of subjects: 59
Study 21831993 — intervention group
Group type: EXPERIMENTAL
Intervention: SFA + LC n-3 PUFA (DHA-rich fish oil)
Number of subjects: 59
Study 20095368 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine 100 mg
Number of subjects: 46
Study 20095368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 17118091 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioids (MS-contin, methadone)
Number of subjects: 37
Study 17118091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 14985219 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg FeSO(4)
Number of subjects: 41
Study 14985219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 11556862 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency thermal ablation tonsillectomy
Number of subjects: 40
Study 11556862 — intervention group
Group type: COMPARATOR
Intervention: Traditional cold dissection tonsillectomy with diathermy hemostasis
Number of subjects: 40
Study 11556862 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 40
Study 10101526 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray (0.56 mg intranasally daily for two weeks)
Number of subjects: 33
Study 10101526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 7828351 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone therapy for 4 months
Number of subjects: 21
Study 7828351 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 4 months
Number of subjects: 21
Study 2455153 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 24
Study 2455153 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 24
Study 30415813 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg/d and Solifenacin 10 mg/d
Number of subjects: 0
Study 30415813 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg/d and Solifenacin 20 mg/d
Number of subjects: 0
Study 30415813 — intervention group
Group type: COMPARATOR
Intervention: Dutasteride 0.5 mg/d
Number of subjects: 0
Study 26754620 — intervention group
Group type: EXPERIMENTAL
Intervention: Endonasal spreader graft surgery with septoplasty and turbinoplasty
Number of subjects: 17
Study 25106783 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT-D)
Number of subjects: 654
Study 25106783 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline galectin-3 level
Number of subjects: 654
Study 24066322 — intervention group
Group type: EXPERIMENTAL
Intervention: Atraumatic flapless procedure
Number of subjects: 19
Study 24066322 — intervention group
Group type: COMPARATOR
Intervention: Conventional flap procedure
Number of subjects: 19
Study 21998206 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA)
Number of subjects: 19
Study 18466078 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of hyperthyroidism
Number of subjects: 47
Study 18466078 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of hypothyroidism
Number of subjects: 47
Study 18466078 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 47
Study 16549905 — intervention group
Group type: EXPERIMENTAL
Intervention: AST-120 (3 g t.i.d.)
Number of subjects: 20
Study 16549905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12735499 — intervention group
Group type: EXPERIMENTAL
Intervention: Watchful waiting
Number of subjects: 0
Study 12735499 — intervention group
Group type: COMPARATOR
Intervention: Pre-PSA era survival analysis
Number of subjects: 0
Study 10959787 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel Matrix Derivative (Emdogain)
Number of subjects: 30
Study 10959787 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Tissue Regeneration (GTR) with ePTFE membranes
Number of subjects: 30
Study 10959787 — intervention group
Group type: COMPARATOR
Intervention: Widman Modified Flap (WMF)
Number of subjects: 30
Study 8874307 — intervention group
Group type: COMPARATOR
Intervention: Blind manual bedside method
Number of subjects: 35
Study 8874307 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonographic bedside technique
Number of subjects: 35
Study 8874307 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonographic technique
Number of subjects: 35
Study 1408537 — intervention group
Group type: EXPERIMENTAL
Intervention: Double phototherapy
Number of subjects: 70
Study 1408537 — intervention group
Group type: COMPARATOR
Intervention: Single phototherapy
Number of subjects: 70
Study 2821151 — intervention group
Group type: EXPERIMENTAL
Intervention: High cereal fibre diet
Number of subjects: 201
Study 2821151 — intervention group
Group type: COMPARATOR
Intervention: Low cereal fibre diet
Number of subjects: 201